Antimicrobial compounds from
Antimicrobial compounds from Bacillus subtilis for use against animal and human pathogens. A novel strain of Bacillus subtilis was isolated from the gastrointestinal tract of poultry and was found to produce a factor or factors that have excellent inhibitory effects on Clostridium perfringens, Clostridium difficile, Campylobacter jejuni, Campylobacter coli, and Streptococcus pneumoniae. The factor(s) retain full viability and antimicrobial activity after heat treatment. The invention provides a method of treatment of pathogenic microorganisms including C. perfringens.
1. A composition, comprising:
a biologically pure culture of viable bacterial cells of the Bacillus subtilis strain deposited under ATCC Accession No. PTA-6737 and a pharmaceutically acceptable carrier.
2. The composition according to claim 1 , wherein the viable bacterial cells are stable for 90 minutes upon exposure to pH 6 and to 0.75% bile salt at pH 2.
3. The composition according to claim 1 , further comprising fermented extracts produced by the cells, the fermented extracts having antimicrobial activities against human and non-human animal pathogens.
4. The composition according to claim 3 , wherein the human and non-human animal pathogens are selected from the group consisting of Clostridium, Campylobacter, Streptococcus and Helicobacter.
5. The composition according to claim 3 , wherein the fermented extracts retain 90% antimicrobial activity against Clostridium perfringens upon exposure to 121° C. for 15 minutes.
6. The composition according to claim 3 , wherein the fermented extracts retain antimicrobial activity against Clostridium perfringens of 60% upon treatment with trypsin, of 44% upon exposure to pronase, and of 79% upon exposure to pepsin.